Orexo: Orexo’s AbstralTM Receives Two Further Large EU Market Approvals In France And Spain

Orexo (STO:ORX), announces that AbstralTM has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain. AbstralTM is expected to be launched during the second half of 2009 in France and Spain, following pricing and reimbursement negotiations with the relevant authorities, by ProStrakan (LSE:PSK), Orexo’s exclusive licensing partner for AbstralTM in Europe and North America.

More: continued here

Filed under: Pain / Anesthetics on March 11th, 2009